These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31629611)

  • 21. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.
    McDonald CM; Marden JR; Shieh PB; Wong BL; Lane H; Zhang A; Nguyen H; Frean M; Trifillis P; Koladicz K; Signorovitch J
    J Comp Eff Res; 2023 Apr; 12(4):e220190. PubMed ID: 36749302
    [No Abstract]   [Full Text] [Related]  

  • 22. Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS.
    Arpan I; Willcocks RJ; Forbes SC; Finkel RS; Lott DJ; Rooney WD; Triplett WT; Senesac CR; Daniels MJ; Byrne BJ; Finanger EL; Russman BS; Wang DJ; Tennekoon GI; Walter GA; Sweeney HL; Vandenborne K
    Neurology; 2014 Sep; 83(11):974-80. PubMed ID: 25098537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electrical impedance myography for assessment of Duchenne muscular dystrophy.
    Rutkove SB; Kapur K; Zaidman CM; Wu JS; Pasternak A; Madabusi L; Yim S; Pacheck A; Szelag H; Harrington T; Darras BT
    Ann Neurol; 2017 May; 81(5):622-632. PubMed ID: 28076894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.
    Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy.
    Mayhew AG; Cano SJ; Scott E; Eagle M; Bushby K; Manzur A; Muntoni F;
    Dev Med Child Neurol; 2013 Nov; 55(11):1046-52. PubMed ID: 23909763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physical Activity in Boys With Duchenne Muscular Dystrophy Is Lower and Less Demanding Compared to Healthy Boys.
    Heutinck L; Kampen NV; Jansen M; Groot IJ
    J Child Neurol; 2017 Apr; 32(5):450-457. PubMed ID: 28112012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hip kinetics during gait are clinically meaningful outcomes in young boys with Duchenne muscular dystrophy.
    Heberer K; Fowler E; Staudt L; Sienko S; Buckon CE; Bagley A; Sison-Williamson M; McDonald CM; Sussman MD
    Gait Posture; 2016 Jul; 48():159-164. PubMed ID: 27267770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?
    Buckon C; Sienko S; Bagley A; Sison-Williamson M; Fowler E; Staudt L; Heberer K; McDonald CM; Sussman M
    PLoS Curr; 2016 Jul; 8():. PubMed ID: 27500011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reliability and validity analyses of the North Star Ambulatory Assessment in Brazilian Portuguese.
    Okama LO; Zampieri LM; Ramos CL; Toledo FO; Alves CRJ; Mattiello-Sverzut AC; Mayhew A; Sobreira CFR
    Neuromuscul Disord; 2017 Aug; 27(8):723-729. PubMed ID: 28648683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy.
    Hibma JE; Jayachandran P; Neelakantan S; Harnisch LO
    CPT Pharmacometrics Syst Pharmacol; 2023 Mar; 12(3):375-386. PubMed ID: 36718719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials.
    Alfano LN; Miller NF; Berry KM; Yin H; Rolf KE; Flanigan KM; Mendell JR; Lowes LP
    Neuromuscul Disord; 2017 May; 27(5):452-457. PubMed ID: 28279570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-sectional evaluation of electrical impedance myography and quantitative ultrasound for the assessment of Duchenne muscular dystrophy in a clinical trial setting.
    Rutkove SB; Geisbush TR; Mijailovic A; Shklyar I; Pasternak A; Visyak N; Wu JS; Zaidman C; Darras BT
    Pediatr Neurol; 2014 Jul; 51(1):88-92. PubMed ID: 24814059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationships between
    Thangarajh M; Hendriksen J; McDermott MP; Martens W; Hart KA; Griggs RC;
    Neurology; 2019 Oct; 93(17):e1597-e1604. PubMed ID: 31594858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ambulatory capacity in Japanese patients with Duchenne muscular dystrophy.
    Awano H; Itoh C; Takeshima Y; Lee T; Matsumoto M; Kida A; Kaise T; Suzuki T; Matsuo M
    Brain Dev; 2018 Jun; 40(6):465-472. PubMed ID: 29551259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and mutational characteristics of Duchenne muscular dystrophy patients based on a comprehensive database in South China.
    Wang DN; Wang ZQ; Yan L; He J; Lin MT; Chen WJ; Wang N
    Neuromuscul Disord; 2017 Aug; 27(8):715-722. PubMed ID: 28318817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy.
    Tsabari R; Simchovitz E; Lavi E; Eliav O; Avrahami R; Ben-Sasson S; Dor T
    Neuromuscul Disord; 2021 Sep; 31(9):803-813. PubMed ID: 34304968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
    Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trial readiness in non-ambulatory boys and men with duchenne muscular dystrophy: MDA-DMD network follow-up.
    Connolly AM; Florence JM; Zaidman CM; Golumbek PT; Mendell JR; Flanigan KM; Karachunski PI; Day JW; McDonald CM; Darras BT; Kang PB; Siener CA; Gadeken RK; Anand P; Schierbecker JR; Malkus EC; Lowes LP; Alfano LN; Johnson L; Nicorici A; Kelecic JM; Quigley J; Pasternak AE; Miller JP;
    Muscle Nerve; 2016 Oct; 54(4):681-9. PubMed ID: 26930423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.